drugset / Trial / NCT03611231
Chidamide Maintenance After Autologous Hematopoietic Stem Cell Transplantation for Relapsed, Refractory or High-risk Lymphoma
Phase 2
Unknown
43 enrolled
Peking University
Hebei Medical University Fourth Hospital · collabPeking University International Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
Chidamide Maintenance Treatment After Autologous Hematopoietic Stem Cell Transplantation in Patients With Relapsed, Refractory or High-risk Lymphoma : a Prospective, Multi-centric, Single Arm, Open Label Phase II Clinical Trial
Timeline
- Start
- 2018-09-01
- Primary completion
- 2020-12-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |